Executive Summary
Single antiplatelet therapy beats dual antiplatelet therapy on mortality after TAVR, not just on bleeding — a finding from the 5,514-patient TRITAVI registry in JACC Advances showing 6-month all-cause mortality of 2.4% with SAPT versus 5.4% with DAPT (adjusted HR 1.69 for DAPT, P=0.002), with the survival gap persisting at 24 months. The signal extends to both cardiovascular and non-cardiovascular death, which means bleeding avoidance alone doesn't explain the benefit. A separate Chinese cohort flags preoperative LVEDD >50.9 mm as an independent predictor of 1-year readmission or death after Venus-A TAVR, reinforcing that late referral is its own mortality risk. Together these findings tighten the case for SAPT as default post-TAVR and sharpen the argument against watchful waiting once LV remodeling is established.
- TRITAVI: SAPT cut 6-month mortality nearly in half versus DAPT (2.4% vs 5.4%) in 5,514 femoral TAVR patients (JACC Advances).
- Preoperative LVEDD >50.9 mm predicted 1-year poor outcome after Venus-A TAVR with AUC 0.843 in a 108-patient retrospective Chinese cohort (Echocardiography).
- German TAVR length-of-stay remains among Europe's longest, with DRG reimbursement actively penalizing early discharge despite international safety data supporting it (Clin Res Cardiol).
- A double-tap deployment technique for real-time hemodynamic optimization during TAVR gets case-report treatment, flagging operator-level refinement as the next efficiency frontier (JACC Case Reports).
- Boston Scientific shares closed at $49.45, down 51% over 6 months, even as analyst consensus holds strong-buy with an $83 target — a widening dislocation worth tracking (market data).
What to watch: Medtronic reports Q4 earnings June 3, with structural heart revenue and Evolut FX+ commentary the key tells for the TAVR franchise heading into summer congress season.
Aortic Valve (TAVR/TAVI)
The antiplatelet question after TAVR is settled in the direction guidelines already pointed — but harder than expected. TRITAVI, a 10,071-patient multicenter registry (n=5,514 after exclusions for anticoagulation indication, non-femoral access, recent PCI, and procedural complications), found SAPT associated with a 6-month all-cause mortality of 2.4% versus 5.4% with DAPT (log-rank P<0.0001), persisting at 24 months (11.7% vs 14.2%, P=0.007). Adjusted HR for DAPT was 1.69 at 6 months. Cardiovascular and non-cardiovascular mortality were both lower with SAPT, which complicates a pure bleeding-mediation story and points to either residual confounding or a real systemic harm from the second agent. Registry, non-randomized — channeling bias toward DAPT in higher-risk patients is the obvious limitation, and the authors acknowledge it. The direction aligns with POPular TAVI and with ACC/AHA 2020 and ESC 2025 recommendations, both of which favor SAPT in the absence of an anticoagulation indication. A separate single-center retrospective study of 108 Venus-A patients found preoperative LVEDD >50.9 mm predicted 1-year readmission or death (AUC 0.843, sensitivity 99.9%, specificity 62%) — a small, non-randomized cohort, but the finding is mechanistically coherent: LV remodeling established before intervention is a mortality signal the surgical literature identified before TAVR existed, and it is the empirical foundation for the ESC 2025 Class IIa recommendation supporting early intervention in asymptomatic severe AS. Late referral costs lives regardless of which valve you implant. A German perspective piece argues DRG reimbursement is now the rate-limiting step on next-day discharge, not safety.
Device & Technology
A JACC Case Reports piece on the "double-tap" technique for real-time hemodynamic optimization during TAVR deployment underscores how much refinement still lives at the operator level rather than the device level. No abstract data — case report only — but the framing fits the broader trajectory of TAVR as a procedure where outcomes increasingly depend on operator workflow, not hardware iteration alone. That trajectory runs directly against the push for next-day discharge: the more intraprocedural physiology optimization matters, the harder it is to defend abbreviated monitoring on the basis of procedural simplicity.
Regulatory & Policy
Germany's TAVR length-of-stay is the longest in Europe, and a narrative review in Clinical Research in Cardiology names the cause directly: DRG reimbursement structures that financially penalize discharge below current thresholds. The authors propose a four-part roadmap — standardized eligibility, protocolized peri-procedural pathways, pilot implementation, and reimbursement realignment. The clinical case for next-day discharge after uncomplicated transfemoral TAVR is established in multiple registries and supported by international consensus. The barrier is fiscal, not medical. The same misalignment exists in every national health system running a DRG-style reimbursement model; the US faces a softer version via CMS site-of-service differentials. When reimbursement architecture lags procedural maturity by a decade, the result is inefficient care that no one can clinically defend.
Surgical vs. Transcatheter Comparisons
No head-to-head data today. The TRITAVI antiplatelet finding has no direct surgical analog — SAVR patients are typically on aspirin alone or warfarin (mechanical valves), and the post-operative bleeding and thrombosis calculus is structurally different. The LVEDD finding from the Venus-A cohort carries more cross-modality weight: a 50.9 mm cutoff for LV end-diastolic dimension predicting poor 1-year outcome reinforces that established LV remodeling does not fully reverse after intervention — a point the surgical literature has made for decades and one that underlies both the EARLY TAVR signal and the ESC 2025 Class IIa recommendation for early intervention in asymptomatic severe AS. For the SAVR-versus-TAVR debate in patients aged 65–75, the question is no longer whether to intervene early. It is which valve — and the ACC/AHA 2020 framework still favors surgery for patients with greater than 10-year life expectancy on durability grounds that the current dataset cannot yet refute.
Valve Industry Stocks
Edwards Lifesciences (EW)
EW closed at $87.08, up 0.66% on the day and effectively flat over six months (+0.47%), sitting at the top of its 52-week range ($72.30–$88.28). Market cap $50.1B, trailing P/E 47, forward P/E 26, beta 0.87. Analyst consensus target $97.15 (27 analysts), recommendation buy. Next earnings July 23, EPS estimate $0.74 on $1.70B revenue. Edwards has outperformed the rest of the structural heart group dramatically — every other name on this list is down 27–51% over the same window. The bull case rests on TAVR volume growth, the pure-play structural heart focus post-Critical Care divestiture, and EVOQUE pulling tricuspid revenue into the model. The bear case is the 47x trailing multiple in a slowing TAVR market.
Medtronic (MDT)
MDT closed at $75.58, down 0.52% on the day and -27% over six months. Market cap $97B, trailing P/E 21, forward P/E 12.5, beta 0.63. Analyst target $107.08 (26 analysts), buy. Earnings June 3, EPS estimate $1.55 on $9.61B revenue. The June 3 print is the proximate catalyst: Evolut FX+ uptake, structural heart growth rate, and any read-through on the SMART trial small-annulus narrative will set the tone. At forward 12.5x, expectations are low.
Abbott (ABT)
ABT closed at $85.94, up 0.31%, down 33% over six months. Market cap $149.7B, trailing P/E 24, forward P/E 14, beta 0.65. Analyst target $118.64 (25 analysts), buy. Earnings July 16, EPS estimate $1.28 on $12.53B revenue. The structural heart franchise — MitraClip, TriClip, Navitor, Tendyne — sits inside a much larger diversified medtech model, so the stock moves on diabetes care and diagnostics as much as on valves. TriClip's Class IIa positioning in ESC 2025 for high-risk symptomatic severe TR is a tailwind that hasn't fully translated to the multiple.
Boston Scientific (BSX)
BSX closed at $49.45, down 2% on the day and -51% over six months — the worst performer in the group. Market cap $73.5B, trailing P/E 21, forward P/E 13, beta 0.62. Analyst target $83.47 (32 analysts), strong-buy. Earnings July 29, EPS estimate $0.83 on $5.40B revenue. The dislocation between price action and analyst sentiment is the widest on the board. ACURATE neo2's post-market data, the SENTINEL embolic protection footprint, and Watchman growth are the structural-heart-adjacent levers. At these levels, the implied skepticism is meaningful, and any positive valve readout could move the stock hard.
Anteris Technologies (AVR.AX)
AVR.AX closed at A$11.98, down 5.37% on the day but up 99% over six months. Market cap A$1.2B, forward P/E -5.49 (pre-revenue), beta 0.59. Single analyst coverage with A$13 target. DurAValve clinical progress is the entire story — small float, binary catalysts, retail-heavy trading. The doubling over six months reflects optimism about the next-generation tissue platform, but execution risk is the dominant variable.
Market outlook: The 50-point spread between EW (+0.5%) and BSX (-51%) over the same six-month window is the structural heart story of 2026 so far. The TRITAVI antiplatelet finding supports TAVR volume durability — fewer post-procedural bleeds and lower mortality strengthen the outpatient and early-discharge case Edwards and Medtronic have been building toward. The German DRG critique points the same direction: procedure economics are maturing faster than reimbursement frameworks, which is bullish for whoever can credibly own the next-day discharge workflow.
What's next: Medtronic's June 3 earnings will set the near-term tone for the TAVR franchise narrative. The structural heart segment commentary — particularly any forward look at low-risk volume mix and Evolut FX+ ramp — is the line to read.